by Scopolamine helps combat motion sickness symptoms such as dizziness and nausea. It acts as an antimuscarinic by blocking muscarinic acetylcholine receptors in the brain and other organs. Scopolamine products are available in various forms such as patches, tablets, and injections for prevention and treatment of motion sickness.
The global Scopolamine Market is estimated to be valued at US$ 3,676.85 Bn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Increasing prevalence of motion sickness is driving the scopolamine market growth. Approximately 60–70% of the general population experience mild sickness during rides, air travel, sea voyages, car travel on curvy roads and gaming through virtual reality headsets. According to a University of Michigan study, around 30% of individuals are highly prone to motion sickness. Adoption of scopolamine patches and oral medications has grown significantly over the past few years owing to rising public awareness regarding motion sickness triggers and accessibility of treatment options. Development of novel delivery formulations such as long-acting injectables and targeted gel patches are some key opportunities that will augment the market growth over the forecast period.
SWOT Analysis
Strength: Scopolamine market has wide range of applications in motion sickness, postoperative nausea, etc. It is a well-established drug with proven effectiveness.
Weakness: Side effects associated with scopolamine like blurred vision, dry mouth, constipation limits its use. Overdose of scopolamine can cause delirium, hallucinations, and confusion.
Opportunity: Growing demand for motion sickness treatment during traveling and demand for nausea drugs during chemotherapy presents growth opportunities. Expanding geriatric population suffering from nausea and vomiting is another growth driver.
Threats: Patents expiry of major drugs and introduction of alternative anti-emetic drugs poses threat to scopolamine market. Stringent regulatory approvals for new drugs and alternative treatment options can hamper the market growth.
Key Takeaways
The global Scopolamine Market Growth is expected to witness high growth. The global Scopolamine Market is estimated to be valued at US$ 3,676.85 Bn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030.
North America dominates the global scopolamine market currently owing to growing geriatric population, increasing prevalence of motion sickness and postoperative nausea and vomiting. However, Asia Pacific is expected to witness fastest growth due to rising healthcare spending, increasing awareness about motion sickness treatment and expanding customer base.
Key players operating in the scopolamine market are Baxter International Inc., GlaxoSmithKline plc, Novartis AG, Perrigo Company plc, Caleb Pharmaceuticals, Inc., Myungmoon Pharma Co. LTD., Alchem International, Phytex Australia, Centroflora-Cms, Alkaloids of Australia, and Fine Chemicals Corporation. GlaxoSmithKline plc leads the market with its scopolamine product tradename Transderm Scop for motion sickness treatment. Novartis AG offers scopolamine product for postoperative nausea with brand name Scopace. Growing generic market poses threat to these major players.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
